Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korean CrystalGenomics Targets U.S. And Europe For Osteoarthritis Product

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's CrystalGenomics plans to conduct a Phase IIb or Phase III osteoarthritis safety and efficacy study for its next-generation NSAID CG100649, possibly in Asia next year following positive results from its Phase IIa clinical study in 25 European clinical centers in Germany, Hungary and Ukraine

You may also be interested in...



Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate

SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe

Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate

SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe

Bausch & Lomb Collaborates With Galapagos On Ophthalmic Disease Candidates

Eye health company joins long list of pharmaceutical firms partnering with Galapagos in past year.

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel